头颈动脉粥样硬化患者诊疗评估的多模态脑影像定量研究

注册号:

Registration number:

ChiCTR2500104803 

最近更新日期:

Date of Last Refreshed on:

2025-06-24 08:56:51 

注册时间:

Date of Registration:

2025-06-24 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

头颈动脉粥样硬化患者诊疗评估的多模态脑影像定量研究

Public title:

Quantitative Study of Multimodal Brain Imaging in the Diagnosis and Assessment of Carotid and Cerebral Atherosclerosis Patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

头颈动脉粥样硬化患者诊疗评估的多模态脑影像定量研究

Scientific title:

Quantitative Study of Multimodal Brain Imaging in the Diagnosis and Assessment of Carotid and Cerebral Atherosclerosis Patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

崔碧霄 

研究负责人:

崔碧霄 

Applicant:

Bixiao Cui 

Study leader:

Bixiao Cui 

申请注册联系人电话:

Applicant telephone:

+86 18311281311

研究负责人电话:

Study leader's
telephone:

+86 10 83199428

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

bixiao1311@163.com

研究负责人电子邮件:

Study leader's E-mail:

bixiao1311@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市西城区长椿街45号

研究负责人通讯地址:

北京市西城区长椿街45号

Applicant address:

No. 45, Changchun Street, Xicheng District, Beijing

Study leader's address:

No. 45, Changchun Street, Xicheng District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学宣武医院

Applicant's institution:

Xuanwu Hospital Capital Medical University

研究负责人所在单位:

首都医科大学宣武医院

Affiliation of the Leader:

Xuanwu Hospital Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

临研审[2025]201号-001

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学宣武医院伦理委员会

Name of the ethic committee:

Ethics Committee of Xuanwu Hospital Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-05-14 00:00:00

伦理委员会联系人:

张卓然

Contact Name of the ethic committee:

Zhuoran Zhang

伦理委员会联系地址:

北京市西城区长椿街45号

Contact Address of the ethic committee:

No. 45, Changchun Street, Xicheng District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 83199270

伦理委员会联系人邮箱:

Contact email of the ethic committee:

xwzhuoranzhang@163.com

研究实施负责(组长)单位:

首都医科大学宣武医院

Primary sponsor:

Xuanwu Hospital Capital Medical University

研究实施负责(组长)单位地址:

北京市西城区长椿街45号

Primary sponsor's address:

No. 45, Changchun Street, Xicheng District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学宣武医院

具体地址:

北京市西城区长椿街45号

Institution
hospital:

Xuanwu Hospital Capital Medical University

Address:

No. 45, Changchun Street, Xicheng District, Beijing

经费或物资来源:

自筹

Source(s) of funding:

Self-funded

研究疾病:

头颈动脉粥样硬化导致的颅内动脉狭窄  

Target disease:

Intracranial artery stenosis due to head and carotid atherosclerosis

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

本项目立足优化脑卒中患者健康服务,针对头颈动脉粥样硬化患者脑组织量化诊疗评估的临床研究问题,通过多模态影像技术,探索药物治疗与手术治疗头颈动脉粥样硬化患者诊疗评估过程中的脑血流代谢量化指标,建立脑血流与脑代谢多模态影像判读头颈动脉粥样硬化患者诊疗客观评估指标。  

Objectives of Study:

This project is based on optimizing health services for stroke patients. Aiming at the clinical research problem of quantitative diagnosis and assessment of brain tissue in patients with carotid and cerebral atherosclerosis, it explores the quantitative indicators of cerebral blood flow and metabolism in the diagnosis and assessment process of patients with carotid and cerebral atherosclerosis treated with drugs or surgery through multimodal imaging technology. It also establishes objective assessment indicators for the diagnosis and treatment of patients with carotid and cerebral atherosclerosis by interpreting multimodal images of cerebral blood flow and metabolism.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.在扫描过程中由于头部移动等原因造成图像质量欠佳;
2.存在可引起脑功能障碍的其他神经系统疾病(如抑郁、脑肿瘤、帕金森病、代谢性脑病、脑炎、多发性硬化、癫痫、脑外伤、正常颅压脑积水等);
3.存在可引起认知障碍的其他系统性疾病,如肝功能不全、肾功能不全、甲状腺功能异常、严重贫血、叶酸和维生素B12缺乏、特殊感染(如梅毒、HIV)、酒精及药物滥用等;
4.存在其他已知可能导致认知障碍的疾病;
5.有严重视、听力障碍、幽闭恐惧症等不能配合MRI检查者;
6.罹患无法配合完成认知检查的疾病;
7.基线期拒绝签署知情同意书;

Exclusion criteria:

1.Poor image quality caused by head movement or other reasons during scanning;
2.Presence of other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson’s disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal pressure hydrocephalus, etc.);
3.Presence of other systemic diseases that can cause cognitive impairment, such as hepatic insufficiency, renal insufficiency, thyroid dysfunction, severe anemia, folic acid and vitamin B12 deficiency, specific infections (such as syphilis, HIV), alcohol and drug abuse, etc;
4.Presence of other known diseases that may cause cognitive impairmentPresence of other known diseases that may cause cognitive impairment;
5.Individuals with severe visual or hearing impairment, claustrophobia, or other conditions that prevent cooperation with MRI examination;
6.Individuals suffering from diseases that make it impossible to cooperate with cognitive examinations;
7.Refusal to sign the informed consent form at baseline;

研究实施时间:

Study execute time:

From 2025-05-01 00:00:00 To 2028-04-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-06-30 00:00:00 To 2027-12-31 00:00:00

干预措施:

Interventions:

组别:

手术治疗组

样本量:

50

Group:

Surgical group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

药物治疗组

样本量:

150

Group:

Medical group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京市 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学宣武医院 

单位级别:

三级甲等 

Institution
hospital:

Xuanwu Hospital Capital Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

治疗结束 6 个月一体化 PET/MR 检查结果

指标类型:

主要指标

Outcome:

Results of integrated PET/MR examination 6 months after the end of treatment

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

治疗后 12 个月一体化 PET/MR 检查结果

指标类型:

主要指标

Outcome:

Results of integrated PET/MR examination at 12 months post-treatment

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

NIHSS、mRS 评分(医生评估)

指标类型:

主要指标

Outcome:

NIHSS, mRS score (physician-assessed)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF;EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF;EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-06-24 08:56:44